Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Certepetide

Peptide · developed by Lisata Therapeutics

Phase 2 Most advanced trial (none active)
LSTA Developer
1 Registered trials

What is Certepetide?

Certepetide (CEND-1, LSTA1) is a peptide given by slow intravenous push alongside standard treatment. It is studied in cholangiocarcinoma and gallbladder cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CEND-1, LSTA1
Drug type
Peptide
Therapy area
Oncology
Developer
Lisata Therapeutics, Inc. (LSTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
7PF4546T2P

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05712356 Phase 2 Cholangiocarcinoma Completed LSTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bile Duct CancerCholangiocarcinomaExtrahepatic CholangiocarcinomaGall Bladder CancerGall Bladder CarcinomaGallbladder CancerGallbladder CarcinomaIntrahepatic Cholangiocarcinoma

More from Lisata Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.

Follow LSTA, the company behind Certepetide

See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LSTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.